company background image
BPMC

Blueprint MedicinesNasdaqGS:BPMC Stock Report

Last Price

US$68.91

Market Cap

US$4.1b

7D

-11.7%

1Y

-32.0%

Updated

23 Jan, 2022

Data

Company Financials +
BPMC fundamental analysis
Snowflake Score
Valuation2/6
Future Growth2/6
Past Performance0/6
Financial Health5/6
Dividends0/6

BPMC Stock Overview

Blueprint Medicines Corporation, a precision therapy company, develops medicines for people with cancer and hematologic disorders, and multiple programs for genomically defined cancers, systemic mastocytosis, and cancer immunotherapy in the United States and Europe.

Blueprint Medicines Competitors

Exelixis

NasdaqGS:EXEL

US$5.5b

Eli Lilly

NYSE:LLY

US$220.4b

Price History & Performance

Summary of all time highs, changes and price drops for Blueprint Medicines
Historical stock prices
Current Share PriceUS$68.91
52 Week HighUS$117.86
52 Week LowUS$68.80
Beta0.72
1 Month Change-37.90%
3 Month Change-32.78%
1 Year Change-32.02%
3 Year Change-0.59%
5 Year Change98.93%
Change since IPO265.18%

Recent News & Updates

Shareholder Returns

BPMCUS BiotechsUS Market
7D-11.7%-7.4%-6.1%
1Y-32.0%-21.7%4.2%

Return vs Industry: BPMC underperformed the US Biotechs industry which returned -22% over the past year.

Return vs Market: BPMC underperformed the US Market which returned 4.2% over the past year.

Price Volatility

Is BPMC's price volatile compared to industry and market?
BPMC volatility
BPMC Average Weekly Movement7.2%
Biotechs Industry Average Movement10.2%
Market Average Movement6.7%
10% most volatile stocks in US Market15.5%
10% least volatile stocks in US Market2.4%

Stable Share Price: BPMC is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 7% a week.

Volatility Over Time: BPMC's weekly volatility (7%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2008476Jeff Albershttps://www.blueprintmedicines.com

Blueprint Medicines Corporation, a precision therapy company, develops medicines for people with cancer and hematologic disorders, and multiple programs for genomically defined cancers, systemic mastocytosis, and cancer immunotherapy in the United States and Europe. The company is developing avapritinib for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of non-advanced SM and other mast cell disorders; and fisogatinib, an orally available and potent inhibitor, which is in Phase 1b/2 trials for the treatment of advanced hepatocellular carcinoma. It is also developing pralsetinib for the treatment of RET-altered non-small cell lung cancer, altered solid tumors, medullary thyroid carcinoma, and other solid tumors; BLU-701 and BLU-945, a selective and potent investigational inhibitors of double-mutant EGFR harboring, which are in preclinical stage for patient with EGFR-driven NSCLC.

Blueprint Medicines Fundamentals Summary

How do Blueprint Medicines's earnings and revenue compare to its market cap?
BPMC fundamental statistics
Market CapUS$4.05b
Earnings (TTM)-US$411.07m
Revenue (TTM)US$107.17m

37.8x

P/S Ratio

-9.9x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
BPMC income statement (TTM)
RevenueUS$107.17m
Cost of RevenueUS$335.34m
Gross Profit-US$228.18m
ExpensesUS$182.89m
Earnings-US$411.07m

Last Reported Earnings

Sep 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-6.99
Gross Margin-212.92%
Net Profit Margin-383.58%
Debt/Equity Ratio0%

How did BPMC perform over the long term?

See historical performance and comparison

Valuation

Is Blueprint Medicines undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: BPMC ($68.91) is trading below our estimate of fair value ($360.44)

Significantly Below Fair Value: BPMC is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: BPMC is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: BPMC is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate BPMC's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: BPMC is overvalued based on its PB Ratio (3.3x) compared to the US Biotechs industry average (1.9x).


Future Growth

How is Blueprint Medicines forecast to perform in the next 1 to 3 years based on estimates from 13 analysts?

54.7%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: BPMC is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: BPMC is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: BPMC is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: BPMC's revenue (40.7% per year) is forecast to grow faster than the US market (9.1% per year).

High Growth Revenue: BPMC's revenue (40.7% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: BPMC is forecast to be unprofitable in 3 years.


Past Performance

How has Blueprint Medicines performed over the past 5 years?

13.1%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: BPMC is currently unprofitable.

Growing Profit Margin: BPMC is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: BPMC is unprofitable, but has reduced losses over the past 5 years at a rate of 13.1% per year.

Accelerating Growth: Unable to compare BPMC's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: BPMC is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (11%).


Return on Equity

High ROE: BPMC has a negative Return on Equity (-32.96%), as it is currently unprofitable.


Financial Health

How is Blueprint Medicines's financial position?


Financial Position Analysis

Short Term Liabilities: BPMC's short term assets ($771.8M) exceed its short term liabilities ($119.7M).

Long Term Liabilities: BPMC's short term assets ($771.8M) exceed its long term liabilities ($110.5M).


Debt to Equity History and Analysis

Debt Level: BPMC is debt free.

Reducing Debt: BPMC has no debt compared to 5 years ago when its debt to equity ratio was 4.9%.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: BPMC has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if BPMC has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Dividend

What is Blueprint Medicines's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate BPMC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate BPMC's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if BPMC's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if BPMC's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of BPMC's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

4.8yrs

Average management tenure


CEO

Jeff Albers (50 yo)

7.5yrs

Tenure

US$6,344,667

Compensation

Mr. Jeffrey W. Albers, also known as Jeff, J.D., MBA, serves as Chairman of the Board at Blueprint Medicines Corporation since June 2021. He has been Independent Director of Kymera Therapeutics, Inc. (Prev...


CEO Compensation Analysis

Compensation vs Market: Jeff's total compensation ($USD6.34M) is about average for companies of similar size in the US market ($USD5.29M).

Compensation vs Earnings: Jeff's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: BPMC's management team is considered experienced (4.8 years average tenure).


Board Members

Experienced Board: BPMC's board of directors are considered experienced (7.5 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 5.6%.


Top Shareholders

Company Information

Blueprint Medicines Corporation's employee growth, exchange listings and data sources


Key Information

  • Name: Blueprint Medicines Corporation
  • Ticker: BPMC
  • Exchange: NasdaqGS
  • Founded: 2008
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$4.055b
  • Shares outstanding: 58.84m
  • Website: https://www.blueprintmedicines.com

Number of Employees


Location

  • Blueprint Medicines Corporation
  • 45 Sidney Street
  • Cambridge
  • Massachusetts
  • 02139-4133
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/01/23 23:04
End of Day Share Price2022/01/21 00:00
Earnings2021/09/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.